Roth Capital Maintains Buy on Nuvectis Pharma, Raises Price Target to $33
Nuvectis Pharma, Inc.
Nuvectis Pharma, Inc. NVCT | 0.00 |
Roth Capital analyst Jonathan Aschoff maintains Nuvectis Pharma (NASDAQ:
NVCT) with a Buy and raises the price target from $20 to $33.